Hasan Jafri of MedImmune and COMBACTE Magnet: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Hasan Jafri has been involved in the design and conduct of multiple Phase 1‐4 clinical studies to assess novel small and large molecules against bacterial, viral and fungal pathogens. Prior to joining MedImmune, Dr. Jafri served as a professor in pediatric infectious diseases and clinical science research at the University of Texas Southwestern Medical Center at Dallas. He was …

Jane Knisely of NIH-NIAID: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Jane Knisely is a Program Officer in the Bacteriology and Mycology Branch of the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Disease, NIH, where she oversees scientific programs related to antimicrobial resistance and antibacterial drug development. Specifically, Jane is the program officer for NIAID’s Antibacterial Resistance Leadership Group, a clinical trials group focused …

Steven Gilman of Contrafect Corporation: Featured Speaker of World Anti-Microbial Resistance Congress

Steven Gilman of Contrafect Corporation: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Gilman most recently served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co. Prior to joining Cubist in 2008, Dr. Gilman served as Chairman of the Board of Directors and Chief Executive Officer of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium …

[WHITEPAPER] Quantitative Urine Culture in cUTI Trials: What is the Problem with Genomix? Part 2

Quantitative Urine Culture in cUTI Trials: What is the Problem With Genomix? Part 2 Courtesy of PSI CRO A continuation of an earlier article by the same name, this article builds upon the first, which discussed the challenges and best practices involved in achieving the ideal outcomes when performing quantitative urine culture studies. The second installment goes on to discuss …

Evolving existing drug classes to meet the challenges of unmet medical needs: navigating regulatory perspectives

“Evolving existing drug classes to meet the challenge of unmet medical needs: navigating regulatory perspectives “

Mark Jones, PhD, Head of Project Management at Basilea Pharmaceutica joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss ‘navigating regulatory perspectives ‘. In this presentation, learn about navigating regulatory perspectives in the context of the unmet medical need for new antifungals . Download the presentation to understand more about: Where will our new antifungals come from? The …

Sumathi Nambiar of FDA: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Sumathi Nambiar is Director of the Division of Anti-Infective Products, Office of Antimicrobial Products, since July 2013. Dr. Nambiar joined the Division of Anti-Infective Products in 2002. In her current role, Dr. Nambiar provides regulatory oversight for anti-infective products, including antibacterial, antifungal, and antiparasitic drugs. Dr. Nambiar is board-certified in pediatrics and pediatric infectious diseases. She completed her pediatric …

Crestone: Novel Drug Discovery Programs for Infectious Diseases

“Crestone: Novel Drug Discovery Programs For Emerging Infectious Diseases”

Thale Jarvis of Crestone joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss ‘novel drug discovery programs for emerging infectious diseases’. In this presentation, learn about CRS3123 for the treatment of Clostridium difficile infections. Download the presentation to understand more about: Crestone’s mission Clostridium difficile infection (CDI) CRS3123: Key advantages vs. competition …and much more! Get your copy …

Chris Houchens of BARDA: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Christopher Houchens, PhD joined the US Government’s Biomedical Advanced Research and Development Authority (BARDA) in April 2012. In his previous role as a BARDA Project Officer, Chris lead multiple interdisciplinary product development teams responsible for advancing the development, manufacture, clinical and non-clinical evaluation, and regulatory approval of novel drugs against multidrug resistant organisms, emerging infectious diseases and biothreat agents. In …

Michael Draper of Sanofi: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Michael Draper is currently the Senior Director of External Science and Partnering and a member of the Science, Strategy & External Innovation and Science Policy group at Sanofi. He has more than 15 years of research and development experience in the pharmaceutical industry at both large and small pharmaceutical companies. After completing his postdoctoral studies, he joined the organization …

Edmund Pezalla of Aetna: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Edmund Pezalla, M.D., MPH, is Aetna’s National Medical Director for Pharmaceutical Policy and Strategy. He is responsible for the integration of pharmacy policy and activities into Aetna’s overall strategy and operations. Dr. Pezalla also serves as the lead clinical spokesperson for Aetna in pharmacy related issues and represents Aetna on industry work groups and conferences. Dr. Pezalla is Aetna’s leading …